CBT-1
Asset
Multidrug resistance modulator / P-glycoprotein inhibitor
- Stage
- Phase 1
- Modality
- Small molecule
- Target
- ABCB1
- 1
- Indication
- 1,324
- Trials
- 1
- Developer
Indications
1Sarcoma
Phase 1, Unknown, NCT03002805, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains2
- Owner and partners1
- Trials1,324
- Evidence for its targets2
- Competitors7
- Signals6
Every asset’s record: target, stage, trials and the evidence behind it.
Updated 7 Oct 2026, 2 sources